Clearmind Medicine Inc.

CSE: CMND

Company Logo

Company Overview

Clearmind is a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic derived therapeutics to solve widespread and under-served health problems including alcohol use disorder. Its primary objective is to research and develop compounds derived from psychedelics and attempt to commercialize them as regulated medicines, foods or supplements. 

The Company's intellectual portfolio currently consists of two patent families, one for binge behavior regulators and the other for an alcoholic beverage substitute. Within these two families the Company has two U.S. patents, one European patent, and allowed applications in China and India and pending divisional applications in Europe and the US related to binge behavior regulators; and a European patent and pending applications in the US, China and India related to the alcohol beverage substitute family.

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

-$5.94

Diluted EPS (ttm)

Management Team

Dr. Adi Zuloff-Shani Ph.D.
Chief Exec. Officer

Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA
CFO & Director

Prof. Mark Haden
VP of Bus. Devel.

Mr. Gilad Babchuk
Head of Strategy & Communication

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
()

Insider Ownership
9%